Table 1

Patient characteristics according to resectability

ResectableBorderline-resectableUnresectable
(n = 34)(n = 35)(n = 35)
Age
Median/range (years)70/56–8467/48–8467/51–82
Sex
Male/female28/629/631/4
Performance status
0/1/2/39/16/8/18/25/2/07/21/5/2
T-Factora
1/2/3/414/11/9/00/2/18/153/3/1/28
N-Factor
0/1/2/321/6/6/16/11/12/62/11/9/13
Stage
1/2/3/418/6/10/00/1/28/60/0/19/16
Operabilityb
Operable/inoperable22/1233/2NAe
Chemotherapy
PF-q4w/PF-low dosec22/1211/24d10/25
ResectableBorderline-resectableUnresectable
(n = 34)(n = 35)(n = 35)
Age
Median/range (years)70/56–8467/48–8467/51–82
Sex
Male/female28/629/631/4
Performance status
0/1/2/39/16/8/18/25/2/07/21/5/2
T-Factora
1/2/3/414/11/9/00/2/18/153/3/1/28
N-Factor
0/1/2/321/6/6/16/11/12/62/11/9/13
Stage
1/2/3/418/6/10/00/1/28/60/0/19/16
Operabilityb
Operable/inoperable22/1233/2NAe
Chemotherapy
PF-q4w/PF-low dosec22/1211/24d10/25

aTwo T2 patients in borderline-resectable had large lymph node metasitasis with probable invasion to surrounding tissues and 7 T1–3 patients in unresectable had cervival or supraclavicular lymph node metastasis; bOperability was judged by surgeons according to patient’s medical condition including comorbidity. This does not mean resectability; cPF-q4w, 2 cycles of cisplatin and 5-fluorouracil every 4 weeks; PF-low dose, cisplatin and 5-fluorouracil 5 days a week for 20 days; dFifteen patients received definitive chemoradiotherapy due to poor response after induction chemoradiotherapy; eNA, not available/operability was not fully evaluated in unresectable patients.

Table 1

Patient characteristics according to resectability

ResectableBorderline-resectableUnresectable
(n = 34)(n = 35)(n = 35)
Age
Median/range (years)70/56–8467/48–8467/51–82
Sex
Male/female28/629/631/4
Performance status
0/1/2/39/16/8/18/25/2/07/21/5/2
T-Factora
1/2/3/414/11/9/00/2/18/153/3/1/28
N-Factor
0/1/2/321/6/6/16/11/12/62/11/9/13
Stage
1/2/3/418/6/10/00/1/28/60/0/19/16
Operabilityb
Operable/inoperable22/1233/2NAe
Chemotherapy
PF-q4w/PF-low dosec22/1211/24d10/25
ResectableBorderline-resectableUnresectable
(n = 34)(n = 35)(n = 35)
Age
Median/range (years)70/56–8467/48–8467/51–82
Sex
Male/female28/629/631/4
Performance status
0/1/2/39/16/8/18/25/2/07/21/5/2
T-Factora
1/2/3/414/11/9/00/2/18/153/3/1/28
N-Factor
0/1/2/321/6/6/16/11/12/62/11/9/13
Stage
1/2/3/418/6/10/00/1/28/60/0/19/16
Operabilityb
Operable/inoperable22/1233/2NAe
Chemotherapy
PF-q4w/PF-low dosec22/1211/24d10/25

aTwo T2 patients in borderline-resectable had large lymph node metasitasis with probable invasion to surrounding tissues and 7 T1–3 patients in unresectable had cervival or supraclavicular lymph node metastasis; bOperability was judged by surgeons according to patient’s medical condition including comorbidity. This does not mean resectability; cPF-q4w, 2 cycles of cisplatin and 5-fluorouracil every 4 weeks; PF-low dose, cisplatin and 5-fluorouracil 5 days a week for 20 days; dFifteen patients received definitive chemoradiotherapy due to poor response after induction chemoradiotherapy; eNA, not available/operability was not fully evaluated in unresectable patients.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close